eli lilly phase 3 trial retatrutide Today, we shared new data from the latest study of retatrutide, an investigational treatment being studied for adults with obesity or overweight with at least one weight-related comorbidity. Learn more Lilly announces more next-gen obesity

Important safety considerations include the risk of pancreatitis (seek urgent medical attention for severe, persistent abdominal pain), gallbladder disease, and dehydration or acute kidney injury from severe gastrointestinal symptoms

Right now, tirzepatide is considered one of the most powerful widely used medications for weight loss because of the significant body weight reductions seen in studies

These typically resolve within 24-48 hours without intervention

Awareness is power

There's also the fact that after weight loss, many people's metabolisms actually slow downmaking it progressively harder to maintain or continue shedding pounds

December 28, 2024